Log In Sign up
The largest database of trusted experimental protocols

Elecsys β amyloid 1 42 csf

Manufactured by Roche
Visit Supplier

The Elecsys β-Amyloid (1-42) CSF is a quantitative electrochemiluminescence immunoassay for the in vitro determination of beta-amyloid 1-42 in human cerebrospinal fluid. It is intended for use on Roche's cobas e analyzers.

Automatically generated - may contain errors

Lab products found in correlation

Total tau csf, by Roche (3 mentions) Phospho tau 181p csf, by Roche (3 mentions) Innotest β amyloid1 42, by Fujirebio (1 mentions) Innotest htau ag, by Fujirebio (1 mentions) Elecsys phospho tau 181p csf, by Roche (1 mentions) Innotest phospho tau 181p, by Fujirebio (1 mentions) Elecsys total tau csf, by Roche (1 mentions)

4 protocols using elecsys β amyloid 1 42 csf

1

Measurement of CSF Biomarkers for Alzheimer's

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF samples (20–40 mL) were collected during the tap tests and collected in 14 mL polypropylene tubes, divided into aliquots of 250 µL, and immediately frozen at − 80 °C until analysis. CSF Aβ1–42, t-tau and p-tau were quantified at the UEF Biomarker Laboratory. Samples were analyzed either with ELISA assays (before 2020, assays Innotest β-amyloid (1–42), Innotest hTAU-Ag, and Innotest Phospho-Tau (181P), Fujirebio Europe, 30–33) or with automated immunoassays (since 2020, assays Elecsys β-Amyloid (1–42) CSF, Elecsys Total Tau CSF, and Elecsys Phospho-Tau (181P) CSF, Roche Diagnostics, 34–35). Due to measurement level differences between Innotest and Elecsys methods [36 (link)], the following conversions were performed to enable direct comparison of the results: Aβ1–42 Elecsys = (1.22 × Aβ1-42 Innotest) + 7.15, t-tau Elecsys = (0.475 × t-tau Innotest) + 66.0, p-tau Elecsys = (0.419 × p-tau Innotest)—3.807). These conversion factors had previously been established by measuring 100 CSF samples with Innotest and Elecsys assays.
Weiner S., Junkkari A., Sauer M., Luikku A., Rauramaa T., Kokkola T., Herukka S.K., Blennow K., Zetterberg H., Leinonen V, & Gobom J. (2023). Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 20, 40.
+ Open protocol
+ Expand
2

Biomarker Analysis in Cerebrospinal Fluid

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF from participants was analyzed with the following assays: Elecsys β-Amyloid (1-42) CSF, Elecsys Total-Tau CSF and Elecsys Phospho-Tau (181P) CSF performed at Roche Diagnostics); NfL (Uman), NfH (Protein Simple, ELLA), YKL40 (Protein Simple, ELLA) and NRGN (Euroimmune) at Immunologix.
Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C, & Lane R.M. (2023). Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine, 29(6), 1437-1447.
+ Open protocol
+ Expand
3

Biomarker Analysis in Cerebrospinal Fluid

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF from participants was analyzed with the following assays: Elecsys β-Amyloid (1-42) CSF, Elecsys Total-Tau CSF and Elecsys Phospho-Tau (181P) CSF performed at Roche Diagnostics); NfL (Uman), NfH (Protein Simple, ELLA), YKL40 (Protein Simple, ELLA) and NRGN (Euroimmune) at Immunologix.
Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C, & Lane R.M. (2023). Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine, 29(6), 1437-1447.
+ Open protocol
+ Expand
4

Biomarker Analysis in Cerebrospinal Fluid

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF from participants was analyzed with the following assays: Elecsys β-Amyloid (1-42) CSF, Elecsys Total-Tau CSF and Elecsys Phospho-Tau (181P) CSF performed at Roche Diagnostics); NfL (Uman), NfH (Protein Simple, ELLA), YKL40 (Protein Simple, ELLA) and NRGN (Euroimmune) at Immunologix.
Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C, & Lane R.M. (2023). Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine, 29(6), 1437-1447.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!